-
2022-500013-32-01
5
2024-07-05
Adrenocortical carcinoma
-
2023-508590-89-00
7
2024-06-25
Multiple Myeloma
-
2022-502404-73-00
4
2024-06-03
Pancreatic ductal adenocarcinoma
-
2023-505436-35-00
5
2024-06-03
Untreated FLIPI 2-5 Follicular Lymphoma
-
2023-507751-30-00
9
2024-05-27
relapsed or refractory multiple myeloma
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2022-501648-14-00
9
2024-05-05
Relapsed or refractory CD19 positive B cell malignancies (adult ALL, a
-
2023-507632-20-00
5
2024-05-01
Multiple Myeloma
-
2022-502751-61-00
4
2024-04-10
Advanced stage III, IVA, IVB laryngeal or II, III, IVA, IVB hypopharyn
-
2023-505141-48-00
5
2024-03-07
Fibrosis
-
2023-503327-26-00
5
2024-01-31
Sjogren's syndrome
-
2022-501941-63-00
7
2023-12-13
Multiple myeloma
-
2023-503490-38-00
4
2023-11-15
critical illness, intensive care unit (ICU), surgery
-
2022-500453-16-00
4
2023-10-30
Multiple Myeloma
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2023-503558-10-00
5
2023-10-13
oligometastatic pancreatic cancer
-
2022-502160-20-00
5
2023-10-02
Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2024-511336-28-00
9
2023-08-11
Leukemia in childhood
-
2022-503133-54-00
7
2023-08-09
Solid Tumors
-
2022-501797-19-00
1
2023-07-13
Acute Myeloid Leukemia (AML)
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph